<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491437</url>
  </required_header>
  <id_info>
    <org_study_id>M13-625</org_study_id>
    <secondary_id>2012-002993-29</secondary_id>
    <nct_id>NCT02491437</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)</brief_title>
  <acronym>LOTUS II</acronym>
  <official_title>A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datamap</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, two-arm and open label study is to demonstrate that the
      treatment of a daily dose of 3x10mg dydrogesterone orally is as effective and safe as the
      daily dose Crinone 8% intravaginal progesterone gel 90 mg for the luteal support in women who
      are unable to conceive a child and are undergoing IVF. The treatment will start on the day of
      oocyte retrieval and continue until pregnancy is negative or until week 12 gestation.

      Patients will be followed during treatment until 30 days after delivery to record any safety
      and tolerability data of the patient and their newborn (s).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;This article has been accepted for publication in Human Reproduction published by Oxford
      University Press.&quot;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound</measure>
    <time_frame>12 weeks´ gestation</time_frame>
    <description>Pregnancy rate defined as the presence of fetal heart beats at 12 weeks' gestation determined by transvaginal ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)</measure>
    <time_frame>Day 14 after embryo transfer</time_frame>
    <description>Positive biochemical pregnancy test on Day 14 after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)</measure>
    <time_frame>After delivery (about 9 months after IVF)</time_frame>
    <description>Live birth rate (percentage of participants with a live birth)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)</measure>
    <time_frame>After delivery (about 9 months after IVF)</time_frame>
    <description>The gender (number of delivered newborns that are male or female)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1034</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone tablets 3x10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dydrogesterone tablets 3x10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crinone 8% intravaginal progesterone gel 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crinone 8% intravaginal progesterone gel 90 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 30 mg</intervention_name>
    <description>Oral Dydrogesterone 10 mg tablets tid</description>
    <arm_group_label>Dydrogesterone tablets 3x10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravaginal progesterone gel 90 mg</intervention_name>
    <arm_group_label>Crinone 8% intravaginal progesterone gel 90 mg</arm_group_label>
    <other_name>Crinone 8% intravaginal progesterone gel 90 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent;

          -  Premenopausal females, age &gt; 18 years &lt; 42 years

          -  Non-smokers. For females who were past smokers, they must have stopped tobacco usage
             for at least 3 months prior screening visit

          -  Early follicular phase (Day 2-4) Follicle stimulating hormone (FSH) less than or equal
             to 15 IU/L and estradiol (E2)within normal limits at screening

          -  luteinizing hormone (LH), prolactin (PRL), T (testosterone) and thyroid-stimulating
             hormone (TSH), within the normal limits for the clinical laboratory, or considered not
             clinically significant by the Investigator within 6 months prior or at screening

          -  Documented history of infertility (e.g., unable to conceive for at least one year or
             for 6 months for women ≥ 38 years of age or bilateral tubal occlusion or absence)

          -  Normal transvaginal ultrasound at screening (or within 14 days prior of screening)
             without evidence of clinically significant abnormality consistent with finding
             adequate for Assisted Reproductive Technology (ART) with respect to uterus and adnexa
             (no hydrosalpinx or clinically relevant uterine fibroids)

          -  Subject is not pregnant , confirmed by negative pregnancy or by Investigator Judgement

          -  Clinically indicated protocol for induction of IVF with a fresh embryo

          -  Single or dual embryo transfer

          -  BMI ≥ 18 and ≤ 30 kg/m2

        Exclusion Criteria:

          -  Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic,
             hematologic/immunologic, HEENT (head, ears, eyes, nose, throat),
             dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,
             neurologic/psychiatric, allergy, recent major surgery (&lt; 3 months), or other relevant
             diseases as revealed by history, physical examination and/or laboratory assessments
             which could limit participation in or completion of the study;

          -  Acute urogenital disease

          -  Known allergic reactions to progesterone products

          -  Known allergic reactions to peanuts and peanut oil

          -  Intake of àny experimental drug or any participation in any other clinical trial
             within 30 days prior to study start

          -  Mental disability or any other lack of fitness, in the Investigator's opinion, to
             preclude subjects to participate in or to complete the study

          -  Current or recent substance abuse, including alcohol and tobacco (Note: Patients who
             stopped tobacco usage at least 3 months prior to screening visit would be allowed)

          -  History of chemotherapy or radiotherapy

          -  Patients with more than 3 unsuccessful IVF attempts

          -  Contraindication for pregnancy

          -  Refusal or inability to comply with the requirements of the study protocol for any
             reason, including scheduled clinic visits and laboratory tests

          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages
             Acute urogenital disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shreyansh Shah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Melbourne IVF</name>
      <address>
        <city>East Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVF Australia - St George Private HospitalIVF Australia - St George Private Hospital</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerité Catholique de Louvain, Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Jan Palfijn Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of Citic -Xiangya</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Second University Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hsopiatl, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliate Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Center Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bielefeld Fertility Center</name>
      <address>
        <city>Bielefeld</city>
        <zip>33619</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderwunschzentrum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Kinderwunschzentrum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United CIIGMA Hospital</name>
      <address>
        <city>Aurangabad</city>
        <zip>431005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MILANN (Bangalore Assisted Conception Center)</name>
      <address>
        <city>Bangalore</city>
        <zip>560001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals - Bangalore</name>
      <address>
        <city>Bangalore</city>
        <zip>560076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110057</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Reproductive Medicine</name>
      <address>
        <city>Kolkata</city>
        <zip>700014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajanta Research Center, Ajanta Hospital and IVF center</name>
      <address>
        <city>Lucknow</city>
        <zip>226005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inamdar Multispecialty Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Hospital and Diagnostic Centre</name>
      <address>
        <city>Pune</city>
        <zip>411006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CJSC &quot;Center of Family Medicine&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Center of Obstetrics, Gynecology and Perinatology n. a. Ac. V. I. Kulakova</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CJSC &quot;Nasledniki&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119192</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Healtcare Institution &quot;Maternity Hospital # 17&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193174</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre of Infertility Treatment &quot;Clinic of Professor Yuzko&quot;</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;NADIYA&quot; Clinic</name>
      <address>
        <city>Kiev</city>
        <zip>03037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Reproductive Medicine in Ukraine</name>
      <address>
        <city>Kiev</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Mother and Child&quot; clinic</name>
      <address>
        <city>Kiev</city>
        <zip>0411</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>China</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <results_first_submitted>July 9, 2019</results_first_submitted>
  <results_first_submitted_qc>September 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02491437/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02491437/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dydrogesterone Tablets 3x10 mg</title>
          <description>Dydrogesterone tablets 3x10 mg
Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid</description>
        </group>
        <group group_id="P2">
          <title>Crinone 8% Intravaginal Progesterone Gel 90 mg</title>
          <description>Crinone 8% intravaginal progesterone gel 90 mg
intravaginal progesterone gel 90 mg OD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="520"/>
                <participants group_id="P2" count="514"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Sample</title>
              <participants_list>
                <participants group_id="P1" count="518"/>
                <participants group_id="P2" count="512"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Sample</title>
              <participants_list>
                <participants group_id="P1" count="494"/>
                <participants group_id="P2" count="489"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="357"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is the full analysis sample</population>
      <group_list>
        <group group_id="B1">
          <title>Dydrogesterone Tablets 3x10 mg</title>
          <description>Dydrogesterone tablets 3x10 mg
Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid</description>
        </group>
        <group group_id="B2">
          <title>Crinone 8% Intravaginal Progesterone Gel 90 mg</title>
          <description>Crinone 8% intravaginal progesterone gel 90 mg
intravaginal progesterone gel 90 mg OD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="494"/>
            <count group_id="B2" value="489"/>
            <count group_id="B3" value="983"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                    <measurement group_id="B2" value="489"/>
                    <measurement group_id="B3" value="983"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="4.4"/>
                    <measurement group_id="B2" value="31.6" spread="4.6"/>
                    <measurement group_id="B3" value="31.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                    <measurement group_id="B2" value="489"/>
                    <measurement group_id="B3" value="983"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="237"/>
                    <measurement group_id="B3" value="487"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound</title>
        <description>Pregnancy rate defined as the presence of fetal heart beats at 12 weeks' gestation determined by transvaginal ultrasound.</description>
        <time_frame>12 weeks´ gestation</time_frame>
        <population>Full Analysis Sample (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone Tablets 3x10 mg</title>
            <description>Dydrogesterone tablets 3x10 mg
Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid</description>
          </group>
          <group group_id="O2">
            <title>Crinone 8% Intravaginal Progesterone Gel 90 mg</title>
            <description>Crinone 8% intravaginal progesterone gel 90 mg
intravaginal progesterone gel 90 mg OD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound</title>
          <description>Pregnancy rate defined as the presence of fetal heart beats at 12 weeks' gestation determined by transvaginal ultrasound.</description>
          <population>Full Analysis Sample (FAS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="34.4" upper_limit="43.1"/>
                    <measurement group_id="O2" value="35.0" lower_limit="30.7" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)</title>
        <description>Positive biochemical pregnancy test on Day 14 after embryo transfer</description>
        <time_frame>Day 14 after embryo transfer</time_frame>
        <population>Full Analysis Sample (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone Tablets 3x10 mg</title>
            <description>Dydrogesterone tablets 3x10 mg
Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid</description>
          </group>
          <group group_id="O2">
            <title>Crinone 8% Intravaginal Progesterone Gel 90 mg</title>
            <description>Crinone 8% intravaginal progesterone gel 90 mg
intravaginal progesterone gel 90 mg OD</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)</title>
          <description>Positive biochemical pregnancy test on Day 14 after embryo transfer</description>
          <population>Full Analysis Sample (FAS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="42.9" upper_limit="51.9"/>
                    <measurement group_id="O2" value="43.8" lower_limit="39.3" upper_limit="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)</title>
        <description>Live birth rate (percentage of participants with a live birth)</description>
        <time_frame>After delivery (about 9 months after IVF)</time_frame>
        <population>Full Analysis Sample (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone Tablets 3x10 mg</title>
            <description>Dydrogesterone tablets 3x10 mg
Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid</description>
          </group>
          <group group_id="O2">
            <title>Crinone 8% Intravaginal Progesterone Gel 90 mg</title>
            <description>Crinone 8% intravaginal progesterone gel 90 mg
intravaginal progesterone gel 90 mg OD</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)</title>
          <description>Live birth rate (percentage of participants with a live birth)</description>
          <population>Full Analysis Sample (FAS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="30.2" upper_limit="38.8"/>
                    <measurement group_id="O2" value="32.5" lower_limit="28.4" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)</title>
        <description>The gender (number of delivered newborns that are male or female)</description>
        <time_frame>After delivery (about 9 months after IVF)</time_frame>
        <population>Full Analysis Sample (FAS). These are the number of delivered babies from the mothers in the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone Tablets 3x10 mg</title>
            <description>Dydrogesterone tablets 3x10 mg
Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid</description>
          </group>
          <group group_id="O2">
            <title>Crinone 8% Intravaginal Progesterone Gel 90 mg</title>
            <description>Crinone 8% intravaginal progesterone gel 90 mg
intravaginal progesterone gel 90 mg OD</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)</title>
          <description>The gender (number of delivered newborns that are male or female)</description>
          <population>Full Analysis Sample (FAS). These are the number of delivered babies from the mothers in the FAS</population>
          <units>number of newborns</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gender male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After signing of informed consent form until 30 days after birth, up to 11 months</time_frame>
      <desc>For Adverse Events reporting the safety sample was used consisting of all subjects which have received at least one administration of study drug (518 subjects in Dydrogesterone, 512 subjects in Micronized Progesterone)</desc>
      <group_list>
        <group group_id="E1">
          <title>Dydrogesterone Tablets 3x10 mg (Maternal)</title>
          <description>Dydrogesterone tablets 3x10 mg
Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid</description>
        </group>
        <group group_id="E2">
          <title>Crinone 8% Intravaginal Progesterone Gel 90 mg (Maternal)</title>
          <description>Crinone 8% intravaginal progesterone gel 90 mg
Intravaginal progesterone gel 90 mg OD</description>
        </group>
        <group group_id="E3">
          <title>Dydrogesterone Tablets (Fetus/Newborn)</title>
          <description>Maternal dosing of Dydrogesterone tablets 3x10 mg
221 subjects at risk=205 live births + 16 abortions/stillbirths</description>
        </group>
        <group group_id="E4">
          <title>Crinone 8% Intravaginal Progesterone Gel (Fetus/Newborn)</title>
          <description>Maternal dosing of Crinone 8% intravaginal progesterone gel 90 mg
201 subjects at risk = 188 live births + 13 abortions/stillbirths</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="512"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>coagulopathies (fetus/newborn)</sub_title>
                <description>The number of fetus/newborn was 221 in the dydrogesterone group and 201 in the micronized progesterone group. Frequencies in the Adverse Event table are provided based on the safety sample.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>rate and rythm disorders NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>ischaemic coronary artery disorders (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac septal defects congenital (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>cardiac disorders congenital NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>persistant foetal circulation disorders (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>muskuloskeletal and connective tissue disorders of limbs congenital (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>renal disorders congenital (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>central nervous system disorder congenital NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>great vessel disorders congenital (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>intestinal disorders congenital (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>lymphatic system disorders congenital (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Non-site specific muscle disorders congenital (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>sex chromosomal abnormalities (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal and abdominal pains (excl oral and throat) (related to the mother)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>flatulence, bloating and distension (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>large intestinal stenosis and obstruction (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>colitis (excl infective) (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>intestinal ulcers and perforation NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infections (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>urinary tract infections (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>viral infections (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>lower respiratory tract and lung infections (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>sepsis, bacteraemia, viraemia and fungaemia NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>infections NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>respiratory syncytial viral infections (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>non-site specific injuries (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>foetal and neonatal diagnostic procedures (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>thyroid neoplasms malignant (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>central nervous system vascular disorders (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>facial cranial nerve disorders (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>encephalopathies NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>structural brain disorders NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>hydrocephalic conditions (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortions spontaneous (related to the mother)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="518"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>maternal complications of pregnancy (related to the mother)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="518"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>labour onset and length abnormalities (related to the mother)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="518"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>abortion not specified as induced or spontaneous (related to the mother)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="518"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>gestational age and weight conditions (related to the mother)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>still birth and foetal death (related to the mother)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypertension associated disorders of pregnancy (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>placental abnormalities (excl neoplasms) (related to the mother)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>haeomorrhagic complications of pregnancy (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>abortion related conditions and complications (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>pregnancy complicated by maternal disorders (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>amniotic fluid and cavity disorders of pregnancy (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>maternal complications of delivery (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>postpartum complications (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>gestational age and weight conditions (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>foetal complications NEC (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>foetal growth complications (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal obstructive disorders (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>urinary tract signs and symptoms (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ovarium and fallopian tube disorders (related to the mother)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="518"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>vulvovaginal disorders (related to the mother)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Uterine disorders (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>neonatal hypoxic conditions (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>pulmonary oedemas (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>breathing abnormalities (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>respiratory failures (excl neonatal) (fetus/newborn)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>induced abortions (related to the mother)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="518"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>obstetric therapeutic procedures (related to the mother)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral embolism and thrombosis (related to the mother)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="512"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="518"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="512"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow sponsor sixty (60) days to review and comment on them.
If the Sponsor requests, the Site shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erik van Leeuwen MSc, PMP</name_or_title>
      <organization>Abbott</organization>
      <phone>+31294479241</phone>
      <email>erik.vanleeuwen@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

